The content on this site is intended for healthcare professionals only
Dr Thierry André talks to ecancertv at the ESMO 14th World Congress on Gastrointestinal Cancer (WCGC) in Barcelona.
As a medical oncologist with an interest in gastrointestinal cancer, Dr André gives his perspective on some of the important topics being discussed at the meeting. Specifically he mentions the use of new drugs for the management of patients with metastatic colorectal cancer (mCRC).
Dr André also talks about the TML study that looked at the continuation of bevacizumab in the second line setting, commenting on results from new subgroup analyses presented at the WCGC.
This programme was supported by BAYER.
Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC
ESMO 2024: Highlights and analysis
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients
ASCO 2024: Lung cancer highlights
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
Immunotherapy significantly increases the number of patients free from bowel cancer
